Mesoblast Limited (ASX:MSB): FY26 Ryoncil Revenue and Cell Therapy Development

Aditi Sarkar

14 October 2026 08:18 PM AEDT

Mesoblast Limited (ASX:MSB): FY26 Ryoncil Revenue and Cell Therapy Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Mesoblast reported FY26 total revenue of US$120.3 million, compared with US$17.2 million in FY25.
RYONCIL generated US$115.2 million of net revenue during its first full year of US commercial sales.
FY26 net loss narrowed to US$57.5 million, while year-end cash totalled US$103 million.
The company continued work on adult graft-versus-host disease and chronic low back pain programmes.
In September 2026, the FDA approved a new potency assay for commercial RYONCIL.

Mesoblast Limited (ASX:MSB) develops and commercialises allogeneic cellular medicines for inflammatory diseases. Its US-approved therapy RYONCIL treats steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children. During FY26, Mesoblast (ASX:MSB) reported its first full year of commercial RYONCIL revenue while progressing studies intended to evaluate additional patient populations and other indications.

RYONCIL Revenue Shapes FY26 Results

For the year ended 30 June 2026, Mesoblast (ASX:MSB) reported total revenue of US$120.3 million, compared with US$17.2 million in the preceding financial year. RYONCIL contributed US$115.2 million in US net product revenue, following a 13.4% gross-to-net adjustment. Reported gross profit was US$103.6 million, while gross profit excluding amortisation reached US$109.7 million.

The company recorded a FY26 net loss of US$57.5 million, narrowing from US$102.1 million in FY25. Its second-half net loss was US$17.3 million. These figures distinguish the growth in commercial product revenue from the company’s overall result, which continued to reflect clinical development, regulatory and other operating expenses.

Cash Flow and Funding Position

Mesoblast (ASX:MSB) reported FY26 net operating cash expenditure of US$43.8 million, compared with US$50.0 million for FY25. Spending in the second half was US$13.4 million. Cash at 30 June 2026 stood at US$103 million.

During FY26, the company established a five-year, US$125.0 million credit facility and drew US$50 million to retire maturing debt obligations. The funding arrangement and operating cash expenditure remain relevant measures alongside RYONCIL receipts when assessing the company’s disclosed financing position.

Clinical Programmes Beyond Paediatric Treatment

The existing US RYONCIL approval relates to paediatric SR-aGvHD. Mesoblast (ASX:MSB) has also commenced a registrational study to evaluate RYONCIL in adults with the condition. Any expansion into adult treatment remains subject to the required clinical evidence and regulatory decisions.

For chronic low back pain, Mesoblast reported in August 2026 that patient treatment had been completed in its pivotal Phase 3 trial of rexlemestrocel-L. Trial completion is a development milestone, not evidence that the treatment has been approved or that efficacy has been established in that programme. The company also reported FDA clearance to proceed with a registrational trial evaluating RYONCIL in children with Duchenne muscular dystrophy.

Manufacturing Oversight and Remaining Risks

On 24 September 2026, Mesoblast (ASX:MSB) announced FDA approval of a new potency assay for commercial RYONCIL. Potency testing forms part of the manufacturing controls used to assess biological product characteristics.

Commercial execution depends on treatment-centre adoption, product supply, reimbursement and clinical use within the approved indication. Research programmes carry separate trial, regulatory and expenditure risks. The outcomes of studies in adults, chronic low back pain and other conditions cannot be inferred from existing paediatric approval.

Key Insights

FY26 marked a shift in Mesoblast’s reported revenue composition as commercial RYONCIL sales became its principal source of revenue. The company nevertheless recorded a net loss and operating cash expenditure. Its 2026 disclosures therefore show two distinct activities: supplying an approved cell therapy in the United States and conducting development programmes whose potential applications remain subject to further evidence and regulatory assessment.

FAQs

Q: What does Mesoblast manufacture?

A:Mesoblast develops allogeneic cellular medicines and commercialises RYONCIL in the United States.

Q: What was Mesoblast’s FY26 revenue?

A:Total revenue was US$120.3 million for the year ended 30 June 2026.

Q: How much net revenue did RYONCIL generate in FY26?

A:RYONCIL generated US$115.2 million of net revenue in its first full US commercial year.

Q: Was Mesoblast profitable in FY26?

A:No. It reported a net loss of US$57.5 million.

Q: Is RYONCIL approved for adults?

A:No. The referenced approval is for paediatric SR-aGvHD; adult use is under evaluation.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.